Cargando…

Tobacco exposure primes the secretion of CCL21 positively associated with tertiary lymphoid structure and response to immunotherapy

BACKGROUND: It has been reported that smoking history as a predictor of immunotherapy efficacy in patients with advanced lung cancer, however, the underlying mechanisms of this phenomenon remain largely unknown. METHODS: The patients with lung adenocarcinoma’s (LUAD) cohort and the orthotopical tran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Xuewen, Wang, Hui, Li, Rutao, Song, Xuming, Zhang, Te, Liang, Yingkuan, Chen, Yu-Zhong, Yu, Xinnian, Mao, Qixing, Xia, Wenjie, Chen, Bing, Xu, Lin, Dong, Gaochao, Jiang, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410842/ https://www.ncbi.nlm.nih.gov/pubmed/37369391 http://dx.doi.org/10.1136/jitc-2023-006939

Ejemplares similares

Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases
por: Zhang, Chong, et al.
Publicado: (2023)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
por: Sun, Xiaoyan, et al.
Publicado: (2022)

KALRN mutations promote antitumor immunity and immunotherapy response in cancer
por: Li, Mengyuan, et al.
Publicado: (2020)

Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
por: Xu, Wenhao, et al.
Publicado: (2023)

Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8(+) T cell infiltration and functional transition
por: Yu, Anze, et al.
Publicado: (2023)

Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
por: Chen, Xiaofeng, et al.
Publicado: (2021)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Reschke, Robin, et al.
Publicado: (2021)

Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study
por: Huang, Weicai, et al.
Publicado: (2023)

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy
por: Shi, Lin, et al.
Publicado: (2023)

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
por: Posner, Atara, et al.
Publicado: (2023)

Is there a link between very early changes of primary and secondary lymphoid organs in (18)F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?
por: Seith, Ferdinand, et al.
Publicado: (2020)

Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images
por: Mu, Wei, et al.
Publicado: (2021)

Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity
por: Sorin, Mark, et al.
Publicado: (2023)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
por: He, Bingxi, et al.
Publicado: (2020)

Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy
por: Shi, Jiawei, et al.
Publicado: (2022)

Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer
por: Bai, Yuezong, et al.
Publicado: (2022)

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes
por: Mazzotta, Marco, et al.
Publicado: (2020)

Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy
por: Qin, Yong, et al.
Publicado: (2020)

Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer
por: Seo, Incheol, et al.
Publicado: (2021)

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
por: Mao, Jinzhu, et al.
Publicado: (2021)

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
por: Kawashima, Shusuke, et al.
Publicado: (2021)

Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma
por: Weng, Jialei, et al.
Publicado: (2023)

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
por: Zhang, Xiaozhen, et al.
Publicado: (2022)

Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets
por: Oldham, Robyn A A, et al.
Publicado: (2020)

Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response
por: LaSalle, Thomas, et al.
Publicado: (2020)

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

Intrahepatic inflammatory IgA(+)PD-L1(high) monocytes in hepatocellular carcinoma development and immunotherapy
por: Sung, Pil Soo, et al.
Publicado: (2022)

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
por: Hwang, Michael, et al.
Publicado: (2022)

On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy
por: Nenclares, Pablo, et al.
Publicado: (2021)

uPAR(+) extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
por: Porcelli, Letizia, et al.
Publicado: (2021)

Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions
por: Abdulrahman, Ziena, et al.
Publicado: (2022)

Machine learning-based integration develops a metabolism-derived consensus model for improving immunotherapy in pancreatic cancer
por: Guo, Yongdong, et al.
Publicado: (2023)

Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer
por: Decazes, Pierre, et al.
Publicado: (2023)

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response
por: Ager, Casey R, et al.
Publicado: (2023)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy
por: Abed, Afaf, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cjlbdkb74e84trs32krrd84u0c